ConductScience.org, home

Paper35559366

Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.

Song Q and 8 others. Am J Transl Res, 2022. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer. Papers, record 35559366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35559366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.
PubMed
Journal
Am J Transl Res
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.74
iCite
Revised in PubMed
2022-07-16
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Song QQiuyan
2Cai YYuanxuan
3Guo KKangyuan
4Li MMin
5Yu ZZaoqin
6Tai QQirui
7Zhao YYuhang
8Zhu XXuan
9Zhang CChengliang

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112888815Hypersensitivity reactions related to oxaliplatin (OHP).Br J Cancer2003https://conductscience.org/library/papers/12888815PubMed
27249508A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther1981https://conductscience.org/library/papers/7249508PubMed
319354063Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.Ann Allergy Asthma Immunol2009https://conductscience.org/library/papers/19354063PubMed
425862137Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.Clin Ther2015https://conductscience.org/library/papers/25862137PubMed
524417770Hypersensitivity to oxaliplatin: clinical features and risk factors.BMC Pharmacol Toxicol2014https://conductscience.org/library/papers/24417770PubMed
621524570Re-challenging patients with oxaliplatin allergy: the successful use of a standardised pre-medication protocol in a single institute.Clin Oncol (R Coll Radiol)2011https://conductscience.org/library/papers/21524570PubMed
711249043Idiosyncratic reaction after oxaliplatin infusion.Ann Oncol2001https://conductscience.org/library/papers/11249043PubMed
819556337Allergic reactions to oxaliplatin in a single institute in Japan.Jpn J Clin Oncol2009https://conductscience.org/library/papers/19556337PubMed
911528251Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.Oncology2001https://conductscience.org/library/papers/11528251PubMed
1014551506Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.Anticancer Drugs2003https://conductscience.org/library/papers/14551506PubMed
1124304429A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.Eur J Cancer Care (Engl)2015https://conductscience.org/library/papers/24304429PubMed
1216282245Hypersensitivity reactions to oxaliplatin: experience in a single institute.Ann Oncol2006https://conductscience.org/library/papers/16282245PubMed
1315648298Hypersensitivity Reactions to oxaliplatin: incidence and management.Oncology (Williston Park)2004https://conductscience.org/library/papers/15648298PubMed
1412478013Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy.Am J Clin Oncol2002https://conductscience.org/library/papers/12478013PubMed
1522987983Prevention and handling of acute allergic and infusion reactions in oncology.Ann Oncol2012https://conductscience.org/library/papers/22987983PubMed
1612453321N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.Clin Colorectal Cancer2002https://conductscience.org/library/papers/12453321PubMed
1722099928Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Clin Colorectal Cancer2012https://conductscience.org/library/papers/22099928PubMed
1812712487Hypersensitivity and idiosyncratic reactions to oxaliplatin.Cancer2003https://conductscience.org/library/papers/12712487PubMed
1921448307Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.Int J Med Sci2011https://conductscience.org/library/papers/21448307PubMed
2034745993Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.Front Oncol2021https://conductscience.org/library/papers/34745993PubMed

See all 39 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42629496Best available evidence for the management of oxaliplatin-induced hypersensitivity reactions, with implications for hepatic arterial infusion chemotherapy (HAIC).Support Care Cancer2026https://conductscience.org/library/papers/42629496PubMed
42201461High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.Int J Clin Oncol2026https://conductscience.org/library/papers/42201461PubMed
41127694Oxaliplatin-Induced Hypersensitivity Reactions Resulting in Respiratory and Cardiac Arrest: A Rare Case.Clin Case Rep2025https://conductscience.org/library/papers/41127694PubMed
40697651Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study.Front Pharmacol2025https://conductscience.org/library/papers/40697651PubMed
40672070A real-world study of oxaliplatin-induced hypersensitivity in colorectal cancer treatment based on the pharmacovigilance system in China: a cohort study.J Gastrointest Oncol2025https://conductscience.org/library/papers/40672070PubMed
39286172Huaier relieves oxaliplatin-induced hepatotoxicity through activation of the PI3K/AKT/Nrf2 signaling pathway in C57BL/6 mice.Heliyon2024https://conductscience.org/library/papers/39286172PubMed
39086615Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan.Ther Adv Drug Saf2024https://conductscience.org/library/papers/39086615PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35559366

GET https://conductscience.org/api/papers/v1/35559366/references?page=2